Sanofi: partnership with Biocorp for Mallya technology
(CercleFinance.com) - Biocorp announces the signing of a partnership agreement with Sanofi for Mallya technology, a connected device for insulin injector pens, a long-term agreement that follows exclusive negotiations in July 2019.
Sanofi thereby acquires the rights to a non-exclusive distribution of Mallya in its current global version, as from 2020. Biocorp is committed to developing a specific and exclusive version of Mallya for SoloStar, Sanofi's insulin pen.
Following this agreement, Sanofi agrees to pay Biocorp a new payment of two million euros on signing the contract, with a third payment of 1.5 million euros expected in 2020, when Mallya is actually launched on the market.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Sanofi thereby acquires the rights to a non-exclusive distribution of Mallya in its current global version, as from 2020. Biocorp is committed to developing a specific and exclusive version of Mallya for SoloStar, Sanofi's insulin pen.
Following this agreement, Sanofi agrees to pay Biocorp a new payment of two million euros on signing the contract, with a third payment of 1.5 million euros expected in 2020, when Mallya is actually launched on the market.
Copyright (c) 2019 CercleFinance.com. All rights reserved.